Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically mean
Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
07:05am, Friday, 17'th Oct 2025
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
07:00am, Friday, 17'th Oct 2025
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
06:00am, Thursday, 16'th Oct 2025
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced
ITM Appoints Annette Breunig as Chief People Officer
05:00am, Monday, 13'th Oct 2025
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Pe
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
08:00am, Wednesday, 08'th Oct 2025
TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
05:09am, Sunday, 05'th Oct 2025
Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts off
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
08:00am, Thursday, 02'nd Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
10:42am, Wednesday, 01'st Oct 2025
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
07:00am, Wednesday, 01'st Oct 2025
TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
02:37pm, Friday, 26'th Sep 2025
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu
